Valneva: Ixchiq vaccine approved in UK
(CercleFinance.com) - Valneva reports that the UK Health Authority (MHRA) has granted marketing authorisation in the UK for its Ixchiq, the world's first and only vaccine against chikungunya, its fourth authorisation after the US, Europe and Canada.
This single-dose vaccine is indicated for active immunization for the prevention of disease caused by the chikungunya virus in people aged 18 and over. It will be produced at Valneva's main manufacturing site in Livingston, Scotland.
The approval of Ixchiq is based on data from the pivotal Phase 3 study, published in The Lancet, which included over 4,000 participants and showed that a single dose of the live attenuated vaccine generated a rapid and robust response.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
This single-dose vaccine is indicated for active immunization for the prevention of disease caused by the chikungunya virus in people aged 18 and over. It will be produced at Valneva's main manufacturing site in Livingston, Scotland.
The approval of Ixchiq is based on data from the pivotal Phase 3 study, published in The Lancet, which included over 4,000 participants and showed that a single dose of the live attenuated vaccine generated a rapid and robust response.
Copyright (c) 2025 CercleFinance.com. All rights reserved.